Atara Biotherapeutics, Inc. (ATRA) stock
ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.70−0.23 (-2.90%)
Close on Nov 13, 2026Market cap $77.29MP/E –Yield –
Atara Biotherapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Atara Biotherapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$12.99M. For fiscal 2025 it was -$50.94M. The highest annual figure on record is -$5.97M in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$50.94M | – |
| FY2024 | Dec 31, 2024 | -$68.72M | – |
| FY2023 | Dec 31, 2023 | -$192.98M | – |
| FY2022 | Dec 31, 2022 | -$270.43M | – |
| FY2021 | Dec 31, 2021 | -$220.52M | – |
| FY2020 | Dec 31, 2020 | -$180.76M | – |
| FY2019 | Dec 31, 2019 | -$235.63M | – |
| FY2018 | Dec 31, 2018 | -$179.77M | – |
| FY2017 | Dec 31, 2017 | -$87.50M | – |
| FY2016 | Dec 31, 2016 | -$60.03M | – |
| FY2015 | Dec 31, 2015 | -$37.16M | – |
| FY2014 | Dec 31, 2014 | -$16.63M | – |
| FY2013 | Dec 31, 2013 | -$5.97M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$879.00K | – |
| Q2 FY2026 | Jun 30, 2026 | -$3.34M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.07M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.70M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.79M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.32M | – |
| Q1 FY2025 | Mar 31, 2025 | -$28.14M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.99M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.65M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.61M | – |
| Q4 FY2023 | Dec 31, 2023 | -$50.41M | – |
| Q3 FY2023 | Sep 30, 2023 | -$51.35M | – |
| Q2 FY2023 | Jun 30, 2023 | -$52.80M | – |
| Q1 FY2023 | Mar 31, 2023 | -$38.43M | – |
| Q4 FY2022 | Dec 31, 2022 | -$56.88M | – |
| Q3 FY2022 | Sep 30, 2022 | -$65.06M | – |
| Q2 FY2022 | Jun 30, 2022 | -$63.96M | – |
| Q1 FY2022 | Mar 31, 2022 | -$84.53M | – |
| Q4 FY2021 | Dec 31, 2021 | -$34.27M | – |
| Q3 FY2021 | Sep 30, 2021 | -$58.98M | – |
| Q2 FY2021 | Jun 30, 2021 | -$61.58M | – |
| Q1 FY2021 | Mar 31, 2021 | -$65.70M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.12M | – |
| Q3 FY2020 | Sep 30, 2020 | -$52.96M | – |
| Q2 FY2020 | Jun 30, 2020 | -$56.64M | – |
| Q1 FY2020 | Mar 31, 2020 | -$67.04M | – |
| Q4 FY2019 | Dec 31, 2019 | -$58.69M | – |
| Q3 FY2019 | Sep 30, 2019 | -$52.15M | – |
| Q2 FY2019 | Jun 30, 2019 | -$54.59M | – |
| Q1 FY2019 | Mar 31, 2019 | -$70.20M | – |
| Q4 FY2018 | Dec 31, 2018 | -$57.42M | – |
| Q3 FY2018 | Sep 30, 2018 | -$48.10M | – |
| Q2 FY2018 | Jun 30, 2018 | -$39.43M | – |
| Q1 FY2018 | Mar 31, 2018 | -$34.82M | – |
| Q4 FY2017 | Dec 31, 2017 | -$24.94M | – |
| Q3 FY2017 | Sep 30, 2017 | -$20.23M | – |
| Q2 FY2017 | Jun 30, 2017 | -$20.30M | – |
| Q1 FY2017 | Mar 31, 2017 | -$22.03M | – |
| Q4 FY2016 | Dec 31, 2016 | -$21.16M | – |
See a number that looks wrong?